Sean Lee CFA, an analyst from H.C. Wainwright, maintained the Buy rating on Dogwood Therapeutics. The associated price target remains the same with $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sean Lee CFA’s rating is based on several key considerations regarding Dogwood Therapeutics. Firstly, the company’s acquisition of SP16, a novel treatment for cancer-related pain, has influenced the financial outlook, despite resulting in a significant non-cash charge. This acquisition is seen as a strategic move to enhance Dogwood’s product pipeline, which is crucial for long-term growth.
Additionally, the upcoming interim results from the Phase 2b study of Halneuron, a promising treatment for chemotherapy-induced neuropathic pain, are anticipated to provide valuable insights into the drug’s efficacy and potential. The study’s progress and the FDA’s special protocol assessment approval for a Phase 3 trial further bolster confidence in the company’s prospects. These factors, combined with a risk-adjusted net present value analysis, underpin the Buy rating and the 12-month price target of $12.00 per share.
According to TipRanks, Lee CFA is a 3-star analyst with an average return of 3.1% and a 33.66% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Dogwood Therapeutics, and Verastem.
In another report released on November 7, Maxim Group also maintained a Buy rating on the stock with a $30.00 price target.